These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1126966)

  • 21. [Studies on the persistence of immunity 15 years after revaccination with measles vaccine].
    Zhonghua Yi Xue Za Zhi; 1989 Jul; 69(7):392-5. PubMed ID: 2598096
    [No Abstract]   [Full Text] [Related]  

  • 22. [Efficacy of measles vaccination in young malnourished African children].
    Monjour L; Bourdillon F; Froment A; Claudio-Ribeiro D; Fabre M; Chastang C; Gentilini M
    Bull Soc Pathol Exot Filiales; 1984; 77(3):271-7. PubMed ID: 6488419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haemagglutination inhibition antibody levels one year after natural measles infection and vaccination.
    Eghafona NO; Ahmad AA; Ezeokoli CD; Emejuaiwe SO
    Microbios; 1991; 67(274):33-6. PubMed ID: 1758308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes.
    Dilraj A; Cutts FT; Bennett JV; Fernandez de Castro J; Cohen B; Coovadia HM
    Pediatr Infect Dis J; 2000 Dec; 19(12):1211-3. PubMed ID: 11144388
    [No Abstract]   [Full Text] [Related]  

  • 25. [Status of immunization against measles in the pediatric population of the province of Ferrara].
    Bezzi TM; Soriani S; Trombini R; Scorrano M
    Minerva Pediatr; 1980 Apr; 32(8):581. PubMed ID: 7393191
    [No Abstract]   [Full Text] [Related]  

  • 26. Measles immunization. Successes and failures.
    Yeager AS; Davis JH; Ross LA; Harvey B
    JAMA; 1977 Jan; 237(4):347-51. PubMed ID: 576165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimum age for measles immunisation: study of pre- and post-immunization level of HI antibody titres.
    Bhatnagar SK; Mohan M; Kumar P; Balaya S; Prabhakar AK; Bhargava SK
    Indian Pediatr; 1981 Sep; 18(9):625-9. PubMed ID: 6797943
    [No Abstract]   [Full Text] [Related]  

  • 28. Measles vaccination. Serologic response and persistence of antibody titer by age at vaccination.
    Biberi-Moroeanu S; Munţiu A; Tiţeica M
    Arch Roum Pathol Exp Microbiol; 1982; 41(4):347-55. PubMed ID: 7171306
    [No Abstract]   [Full Text] [Related]  

  • 29. Atypical measles in adolescent siblings 16 years after killed measles virus vaccine.
    Fulginiti VA; Helfer RE
    JAMA; 1980 Aug 22-29; 244(8):804-6. PubMed ID: 7392190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune status following measles vaccination in infants and evaluation for the need of revaccination.
    Dutta AK; Singhal PK; Khare S; Kumari S; Mathur R; Mullick DN
    Indian Pediatr; 1989 Aug; 26(8):765-72. PubMed ID: 2620977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody titres after measles vaccine.
    Ghosh S; Kumari S; Bhargava SK
    Indian J Med Res; 1977 Aug; 66(2):165-71. PubMed ID: 924590
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial: Vaccination against measles.
    Lancet; 1976 Jul; 2(7977):132-4. PubMed ID: 59191
    [No Abstract]   [Full Text] [Related]  

  • 33. Measles susceptibility in two Pacific atoll populations. Epidemiological factors and response to live attenuated measles virus.
    Willis MF; Warburton MF
    Med J Aust; 1974 May; 1(20):789-93. PubMed ID: 4853112
    [No Abstract]   [Full Text] [Related]  

  • 34. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination.
    Dilraj A; Sukhoo R; Cutts FT; Bennett JV
    Vaccine; 2007 May; 25(21):4170-4. PubMed ID: 17408818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children.
    Arpadi SM; Markowitz LE; Baughman AL; Shah K; Adam H; Wiznia A; Lambert G; Dobroszycki J; Heath JL; Bellini WJ
    Pediatrics; 1996 May; 97(5):653-7. PubMed ID: 8628602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effectiveness of selective anti-measles reimmunization of risk-group children].
    Sokhin AA; Ignatov SA
    Pediatriia; 1988; (9):69-72. PubMed ID: 3200643
    [No Abstract]   [Full Text] [Related]  

  • 38. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].
    Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N
    Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
    Ogunmekan DA; Harry TO
    Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Measles vaccination: study of humoral immunity in children vaccinated in the Tunis region].
    Arrouji A; Mirchamsy H; Marnissi A
    Arch Inst Pasteur Tunis; 1982 Mar; 59(1):173-80. PubMed ID: 7181563
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.